Experimental evidence for electroacupuncture in managing pain from chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
4 affiliations
- 1The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China
- 2Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China
- 3Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China
- 4The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China
Abstract
This study systematically evaluated the evidence from animal experiments on electroacupuncture (EA) for chemotherapy-induced peripheral neuropathy (CIPN) pain models. A systematic review and meta-analysis was conducted using the PICOS framework to assess the behavioral and molecular effects of EA and clarify its underlying mechanisms and translational potential. Thirteen eligible studies involving 235 animals were included. Methodological quality scores ranged from 5 to 8, with a mean of 6.5. Meta-analysis showed that EA significantly increased the paw withdrawal threshold (PWT), thermal pain withdrawal latency (PWL), and nerve conduction velocity (NCV), while reducing cold allodynia. At the molecular level, EA significantly decreased the expression of pro-inflammatory and sensitization markers, including TNF-α, IL-1β, GFAP, TLR4, TRPA1, and TRPV1, and increased the oxidative stress regulator Nrf2. Sensitivity analysis, publication bias assessment, subgroup analysis, and meta-regression were performed for the highly heterogeneous PWT outcome. Significant publication bias was identified and may account for much of the observed heterogeneity. Sensitivity analysis for TRPV1 suggested that this result may be disproportionately influenced by individual studies and should therefore be interpreted cautiously. Heterogeneity in the remaining outcomes likely reflects differences in animal models, acupoint selection, treatment duration, and intervention protocols. Overall, EA demonstrated analgesic and neuroprotective effects in CIPN models, primarily through modulation of neuroinflammation, attenuation of oxidative stress, and reduction of neuronal sensitization. These findings provide systematic preclinical evidence supporting EA as a promising adjuvant therapy for CIPN pain and highlight the need for high-quality clinical trials to optimize treatment protocols and facilitate clinical translation.
Related
- Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
- Effect of cryotherapy on chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes: a systematic review using the GRADE system.
- Effects of sensorimotor training on chemotherapy-induced peripheral neuropathy-related outcomes in adults with cancer: A systematic review and meta-analysis of randomized controlled trials.
- Electroacupuncture Attenuates Neuroinflammation and Improves Metabolic Dysregulation in a Mouse Model of Painful Diabetic Peripheral Neuropathy: A Multi-Omics Study
- Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study
BibTeX
@article{kong2026experimental,
title = {{Experimental evidence for electroacupuncture in managing pain from chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis}},
author = {Ying Kong and Lei You and Mengwan Hu and Qiyuan Tian and Hong Sun and Kai Liu and Pengfei Li and Ping Song and Jingang Li},
journal = {Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas},
year = {2026},
month = oct,
doi = {10.1590/1414-431x2026e15562},
url = {https://europepmc.org/article/PMC/PMC13722001},
note = {CC BY},
}
RIS
TY - JOUR
TI - Experimental evidence for electroacupuncture in managing pain from chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
AU - Ying Kong
AU - Lei You
AU - Mengwan Hu
AU - Qiyuan Tian
AU - Hong Sun
AU - Kai Liu
AU - Pengfei Li
AU - Ping Song
AU - Jingang Li
PY - 2026
DA - 2026/10/30
JO - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
DO - 10.1590/1414-431x2026e15562
UR - https://europepmc.org/article/PMC/PMC13722001
AB - This study systematically evaluated the evidence from animal experiments on electroacupuncture (EA) for chemotherapy-induced peripheral neuropathy (CIPN) pain models. A systematic review and meta-analysis was conducted using the PICOS framework to assess the behavioral and molecular effects of EA and clarify its underlying mechanisms and translational potential. Thirteen eligible studies involving 235 animals were included. Methodological quality scores ranged from 5 to 8, with a mean of 6.5. Meta-analysis showed that EA significantly increased the paw withdrawal threshold (PWT), thermal pain withdrawal latency (PWL), and nerve conduction velocity (NCV), while reducing cold allodynia. At the molecular level, EA significantly decreased the expression of pro-inflammatory and sensitization markers, including TNF-α, IL-1β, GFAP, TLR4, TRPA1, and TRPV1, and increased the oxidative stress regulator Nrf2. Sensitivity analysis, publication bias assessment, subgroup analysis, and meta-regression were performed for the highly heterogeneous PWT outcome. Significant publication bias was identified and may account for much of the observed heterogeneity. Sensitivity analysis for TRPV1 suggested that this result may be disproportionately influenced by individual studies and should therefore be interpreted cautiously. Heterogeneity in the remaining outcomes likely reflects differences in animal models, acupoint selection, treatment duration, and intervention protocols. Overall, EA demonstrated analgesic and neuroprotective effects in CIPN models, primarily through modulation of neuroinflammation, attenuation of oxidative stress, and reduction of neuronal sensitization. These findings provide systematic preclinical evidence supporting EA as a promising adjuvant therapy for CIPN pain and highlight the need for high-quality clinical trials to optimize treatment protocols and facilitate clinical translation.
SN - 0100-879X
SN - 1414-431X
ER -